Pamoic acid is a potent GPR35 agonist with an EC50 of 79 nM. Pamoic acid exhibits neuroprotective and anti-inflammatory properties[2].IC50 & Target: EC50: 79 nM (GPR35)In Vitro: GPR35 activation by Pamoic acid may increase the phosphorylation of ERK1/2, which in turn initiates an anti-inflammatory signal by suppressing NF-κB-dependent inflammatory genes.In Vivo: In a mouse model of stroke, that GPR35 activation by Pamoic acid (s.c.; 50-100?mg/kg) is neuroprotective. Pharmacological inhibition of GPR35 reveals that Pamoic acid reduces infarcts size in a GPR35 dependent manner. Pamoic acid treatment results in a preferential increment of noninflammatory Ly-6CLo monocytes/macrophages in the ischemic brain along with the reduced neutrophil counts.